CMC2.24

CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis[1][2][3].

Product Specifications

CAS Number

[1255639-43-0]

Product Name Alternative

TRB-N0224

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; MMP; Ras

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cmc2-24.html

Purity

97.48

Solubility

DMSO : < 1 mg/mL

Smiles

O=C(NC1=CC=CC=C1)C(C(/C=C/C2=CC=C(O)C=C2)=O)C(/C=C/C3=CC=C(O)C=C3)=O

Molecular Formula

C26H21NO5

Molecular Weight

427.45

Precautions

H302, H315, H319

References & Citations

[1]Mallangada NA, et al. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Mol Carcinog. 2018;57 (9) :1130-1143.|[2]Zhou Y, et al. Chemically modified curcumin (CMC2.24) alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis. J Mol Med (Berl) . 2020;98 (10) :1479-1491.|[3]Zhang Y, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19 (25) :4348-4358.